Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
Rhea-AI Summary
Syndax Pharmaceuticals (Nasdaq:SNDX) will host an R&D Day on July 14, 2026, at 8:30 AM ET in New York City. Management and key opinion leaders will present updates on late-stage revumenib and axatilimab programs and discuss ongoing trials.
The event will also cover new early-stage assets and plans to leverage company capabilities to bring additional cancer treatment options to patients. A live webcast and limited-time replay will be available in the Investor section of www.syndax.com.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: ARDX -3.59%, VERA -0.78%, while BHVN +2.94% and VRDN +1.5%, with TRML 0%. This points to stock-specific dynamics rather than a unified biotech sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 21 | ASCO abstracts accepted | Positive | +0.9% | Multiple Revuforj abstracts accepted for ASCO 2026, including oral presentation. |
| May 20 | Investor conferences | Positive | +3.6% | Participation in several major healthcare investor conferences with management presentations. |
| May 12 | EHA abstracts accepted | Positive | -4.5% | Twelve Revuforj abstracts accepted for EHA 2026 across leukemia settings. |
| May 06 | Inducement grants | Neutral | -0.5% | Stock option inducement awards granted to new employees under 2023 Inducement Plan. |
| Apr 30 | Q1 2026 earnings | Positive | -10.8% | Reported strong Q1 revenue growth and reiterated high 2026 R&D and SG&A outlook. |
Recent news has produced mixed reactions: scientific and conference updates sometimes aligned positively, while major data-heavy updates like earnings and large abstract packages saw negative divergence.
Over the past few months, Syndax reported strong commercial progress with Revuforj and Niktimvo, including Q1 2026 revenue of $64.9M and guidance toward extensive 2026 R&D and SG&A spending. Scientific visibility has been high, with multiple Revuforj abstracts accepted at EHA 2026 and ASCO 2026. The stock reaction has varied, including a -10.83% move on Q1 results and a -4.54% move on the large EHA abstract package. Today’s R&D Day announcement fits this pattern of ongoing pipeline and data communication.
Market Pulse Summary
This announcement schedules an R&D Day to highlight late-stage programs such as revumenib and axatilimab, along with new early-stage assets, on July 14, 2026. It continues a pattern of active scientific and investor communication following recent ASCO and EHA abstract acceptances and Q1 2026 results. Investors may watch for detailed data on idiopathic pulmonary fibrosis, chronic graft-versus-host disease, and acute leukemia programs, as well as broader pipeline and strategy updates.
Key Terms
idiopathic pulmonary fibrosis medical
chronic graft-versus-host disease medical
acute leukemia medical
AI-generated analysis. Not financial advice.
NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will host an R&D Day on Tuesday, July 14, 2026, at 8:30 AM ET in New York City. The R&D Day will feature presentations by Syndax’s management team and key opinion leaders.
The Company will highlight its late-stage revumenib and axatilimab programs, including its ongoing trials in idiopathic pulmonary fibrosis, newly diagnosed chronic graft-versus-host disease, and newly diagnosed acute leukemia. Further, the Company will detail its new early-stage assets and broader plans to leverage its capabilities and resources to bring new treatment options to more patients.
A live webcast of the event will be available on the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
